Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

1.

A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.

Hainsworth JD, Schnabel CA, Erlander MG, Haines DW 3rd, Greco FA.

Clin Colorectal Cancer. 2012 Jun;11(2):112-8. doi: 10.1016/j.clcc.2011.08.001. Epub 2011 Oct 14.

PMID:
22000811
[PubMed - indexed for MEDLINE]
2.

Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.

Pentheroudakis G, Greco FA, Pavlidis N.

Cancer Treat Rev. 2009 May;35(3):221-7. doi: 10.1016/j.ctrv.2008.10.003. Epub 2008 Nov 28. Review.

PMID:
19046817
[PubMed - indexed for MEDLINE]
3.

Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.

Hainsworth JD, Greco FA.

Virchows Arch. 2014 Apr;464(4):393-402. doi: 10.1007/s00428-014-1545-2. Epub 2014 Feb 1. Review.

PMID:
24487792
[PubMed - indexed for MEDLINE]
4.

Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature.

Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N.

Cancer Treat Rev. 2008 Dec;34(8):693-700. doi: 10.1016/j.ctrv.2008.05.005. Epub 2008 Jun 26. Review.

PMID:
18584969
[PubMed - indexed for MEDLINE]
5.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

PMID:
18462574
[PubMed - indexed for MEDLINE]
Free Article
6.

Overview of various techniques/platforms with critical evaluation of each.

Agwa E, Ma PC.

Curr Treat Options Oncol. 2013 Dec;14(4):623-33. doi: 10.1007/s11864-013-0259-z. Review.

PMID:
24243164
[PubMed - indexed for MEDLINE]
7.

Cancer of unknown primary site.

Pavlidis N, Pentheroudakis G.

Lancet. 2012 Apr 14;379(9824):1428-35. doi: 10.1016/S0140-6736(11)61178-1. Epub 2012 Mar 12. Review.

PMID:
22414598
[PubMed - indexed for MEDLINE]
8.

[Hepatic metastasis of unknown primary site].

Mousseau M, Schaerer R, Lutz JM, Ménégoz F, Faure H, Swiercz P.

Bull Cancer. 1991;78(8):725-36. Review. French.

PMID:
1932839
[PubMed - indexed for MEDLINE]
9.

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.

Kaltsas GA, Mukherjee JJ, Isidori A, Kola B, Plowman PN, Monson JP, Grossman AB, Besser GM.

Clin Endocrinol (Oxf). 2002 Aug;57(2):169-83. Review.

PMID:
12153595
[PubMed - indexed for MEDLINE]
10.

A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site.

Park YH, Ryoo BY, Choi SJ, Yang SH, Kim HT.

Jpn J Clin Oncol. 2004 Nov;34(11):681-5. Review.

PMID:
15613558
[PubMed - indexed for MEDLINE]
Free Article
11.

A systematic overview of chemotherapy effects in colorectal cancer.

Ragnhammar P, Hafström L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):282-308. Review.

PMID:
11441937
[PubMed - indexed for MEDLINE]
12.

Molecular classification of cancers of unknown primary site.

Greco FA, Erlander MG.

Mol Diagn Ther. 2009 Dec 1;13(6):367-73. doi: 10.2165/11530360-000000000-00000. Review.

PMID:
19925034
[PubMed - indexed for MEDLINE]
13.

Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.

Greco FA.

Curr Treat Options Oncol. 2013 Dec;14(4):634-42. doi: 10.1007/s11864-013-0257-1. Review.

PMID:
23990214
[PubMed - indexed for MEDLINE]
14.

Cancer of unknown primary site: evolving understanding and management of patients.

Greco FA.

Clin Adv Hematol Oncol. 2012 Aug;10(8):518-24. Review.

PMID:
23073050
[PubMed - indexed for MEDLINE]
15.

Management of "unfavourable" carcinoma of unknown primary site: synthesis of recent literature.

Amela EY, Lauridant-Philippin G, Cousin S, Ryckewaert T, Adenis A, Penel N.

Crit Rev Oncol Hematol. 2012 Nov;84(2):213-23. doi: 10.1016/j.critrevonc.2012.03.003. Epub 2012 Apr 11. Review.

PMID:
22503530
[PubMed - indexed for MEDLINE]
16.

Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes.

Greco FA, Oien K, Erlander M, Osborne R, Varadhachary G, Bridgewater J, Cohen D, Wasan H.

Ann Oncol. 2012 Feb;23(2):298-304. doi: 10.1093/annonc/mdr306. Epub 2011 Jun 27. Review.

PMID:
21709138
[PubMed - indexed for MEDLINE]
Free Article
17.

Prognostication in cancer of unknown primary (CUP): development of a prognostic algorithm in 311 cases and review of the literature.

Petrakis D, Pentheroudakis G, Voulgaris E, Pavlidis N.

Cancer Treat Rev. 2013 Nov;39(7):701-8. doi: 10.1016/j.ctrv.2013.03.001. Epub 2013 Apr 6. Review.

PMID:
23566573
[PubMed - indexed for MEDLINE]
18.

What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trials.

Penel N, Ryckewaert T, Kramar A.

Bull Cancer. 2014 Apr;101(4):E19-24. doi: 10.1684/bdc.2014.1934. Review.

PMID:
24793622
[PubMed - indexed for MEDLINE]
19.

Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks.

Kamposioras K, Pentheroudakis G, Pavlidis N.

Eur J Clin Invest. 2013 May;43(5):491-500. doi: 10.1111/eci.12062. Epub 2013 Mar 11. Review.

PMID:
23480555
[PubMed - indexed for MEDLINE]
20.

Long-term survivors among patients with cancer of unknown primary.

Pavlidis N, Petrakis D, Golfinopoulos V, Pentheroudakis G.

Crit Rev Oncol Hematol. 2012 Oct;84(1):85-92. doi: 10.1016/j.critrevonc.2012.02.002. Epub 2012 Mar 2. Review.

PMID:
22386806
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk